Synthesis and absorption markers of cholesterol in serum and lipoproteins during a large dose of statin treatment
- PMID: 14636301
- DOI: 10.1046/j.1365-2362.2003.01229.x
Synthesis and absorption markers of cholesterol in serum and lipoproteins during a large dose of statin treatment
Abstract
Background: Serum contains noncholesterol sterols, which are reliable markers of cholesterol metabolism, but their presence and importance in different lipoproteins have been insufficiently studied.
Materials and methods: Serum and lipoprotein cholesterol precursors squalene, cholestanol, desmosterol and lathosterol (markers of cholesterol synthesis) and cholestanol and plant sterols (markers of cholesterol absorption), and absorption efficacy and absolute synthesis of cholesterol were studied at baseline and during 6-month atorvastatin (80 mg day(-1)) treatment by the sterol balance technique in men with type 2 diabetes.
Results: At baseline, approximately 14% of serum squalene was transported by VLDL, 12% by IDL, 40% by LDL and 30% by HDL. The respective values for the noncholesterol sterols were approximately 8, 4, 61 and 26%. The squalene to cholesterol ratios were highest in VLDL and IDL, those of cholestanol, desmosterol and absorption marker sterols were gradually higher, and that of lathosterol lower from VLDL to HDL. Atorvastatin reduced LDL cholesterol by approximately 50%, decreased the absolute cholesterol synthesis and turnover by approximately 40%, but increased significantly the fractional and mass absorption of cholesterol. In accordance with the fecal data, the ratios of the precursor sterols to cholesterol were reduced (-50%), but those of squalene (+48%) and the absorption sterols increased (e.g. 2.6-fold for sitosterol) similarly in each lipoprotein, but progressively from VLDL to HDL.
Conclusions: Effective lowering of LDL cholesterol by large dose of statin is associated with decreased synthesis and turnover of cholesterol and increased fractional and mass absorption of cholesterol. These changes are detectable by noncholesterol sterols in serum and in different lipoprotein fractions.
Similar articles
-
The distribution of squalene and non-cholesterol sterols in lipoproteins in type 2 diabetes.Atherosclerosis. 2007 Sep;194(1):222-9. doi: 10.1016/j.atherosclerosis.2006.07.030. Epub 2006 Sep 11. Atherosclerosis. 2007. PMID: 16963050
-
Squalene and noncholesterol sterols in serum and lipoproteins of children with and without familial hypercholesterolemia.Pediatr Res. 2003 Apr;53(4):648-53. doi: 10.1203/01.PDR.0000055771.28409.40. Epub 2003 Jan 29. Pediatr Res. 2003. PMID: 12612218
-
Serum noncholesterol sterols during inhibition of cholesterol synthesis by statins.J Lab Clin Med. 2003 Feb;141(2):131-7. doi: 10.1067/mlc.2003.9. J Lab Clin Med. 2003. PMID: 12577049 Clinical Trial.
-
[Change in the cholesterol metabolism associated with the combined inhibition of synthesis and absorption].Orv Hetil. 2007 Apr 8;148(14):627-32. doi: 10.1556/OH.2007.28065. Orv Hetil. 2007. PMID: 17403635 Review. Hungarian.
-
Effect of statins on noncholesterol sterol levels: implications for use of plant stanols and sterols.Am J Cardiol. 2005 Jul 4;96(1A):40D-46D. doi: 10.1016/j.amjcard.2005.03.019. Am J Cardiol. 2005. PMID: 15992515 Review.
Cited by
-
Baseline cholesterol absorption and the response to ezetimibe/simvastatin therapy: a post-hoc analysis of the ENHANCE trial.J Lipid Res. 2010 Apr;51(4):755-62. doi: 10.1194/jlr.M001487. Epub 2009 Oct 14. J Lipid Res. 2010. PMID: 19828909 Free PMC article. Clinical Trial.
-
Approach to the Patient With a Suboptimal Statin Response: Causes and Algorithm for Clinical Management.J Clin Endocrinol Metab. 2023 Aug 18;108(9):2424-2434. doi: 10.1210/clinem/dgad153. J Clin Endocrinol Metab. 2023. PMID: 36929838 Free PMC article. Review.
-
Pharmacology of Nutraceuticals with Lipid Lowering Properties.High Blood Press Cardiovasc Prev. 2019 Apr;26(2):113-118. doi: 10.1007/s40292-019-00311-x. Epub 2019 Mar 15. High Blood Press Cardiovasc Prev. 2019. PMID: 30877602 Review.
-
Anagliptin Monotherapy for Six Months in Patients With Type 2 Diabetes Mellitus and Hyper-Low-Density Lipoprotein Cholesterolemia Reduces Plasma Levels of Fasting Low-Density Lipoprotein Cholesterol and Lathosterol: A Single-Arm Intervention Trial.J Clin Med Res. 2021 Nov;13(10-11):502-509. doi: 10.14740/jocmr4623. Epub 2021 Nov 20. J Clin Med Res. 2021. PMID: 34925661 Free PMC article.
-
Association between cholesterol synthesis/absorption markers and effects of cholesterol lowering by atorvastatin among patients with high risk of coronary heart disease.J Lipid Res. 2013 Nov;54(11):3189-97. doi: 10.1194/jlr.P040360. Epub 2013 Aug 20. J Lipid Res. 2013. PMID: 23964121 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical